BioLife Solutions (NASDAQ:BLFS) EVP Sells $10,363.95 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 405 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total value of $10,363.95. Following the completion of the transaction, the executive vice president directly owned 349,350 shares in the company, valued at $8,939,866.50. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

BioLife Solutions Stock Down 0.4%

Shares of NASDAQ:BLFS opened at $24.86 on Friday. The stock has a market capitalization of $1.20 billion, a PE ratio of -355.09 and a beta of 1.93. The firm’s 50 day moving average price is $25.41 and its 200-day moving average price is $24.85. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in BioLife Solutions by 762.8% in the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after purchasing an additional 617,320 shares during the period. Qube Research & Technologies Ltd boosted its position in shares of BioLife Solutions by 2,399.5% during the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after buying an additional 238,533 shares during the period. Summit Creek Advisors LLC bought a new position in shares of BioLife Solutions during the third quarter valued at approximately $4,905,000. Mutual of America Capital Management LLC grew its stake in shares of BioLife Solutions by 22.2% during the second quarter. Mutual of America Capital Management LLC now owns 638,373 shares of the medical equipment provider’s stock valued at $13,751,000 after buying an additional 115,963 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock worth $23,271,000 after buying an additional 109,959 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Trending Headlines about BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst support that could limit downside — Northland has a $34 target and UBS maintains a buy rating; MarketBeat shows a consensus “Hold” with an average price target near $32, which provides a possible upside reference for investors. MarketBeat BLFS Analyst Coverage
• Neutral Sentiment: Company announced the planned retirement of a key quality & operations executive (effective date/details in the filing). A planned/announced retirement can be orderly but raises succession and continuity questions for manufacturing/quality functions. BioLife announces planned retirement
• Neutral Sentiment: Analysts are issuing Q1 earnings forecasts for BLFS; investors should watch upcoming guidance/quarterly results for confirmation of demand trends in cryopreservation and cell/gene therapy supply chains. Analysts Issue Forecasts for BLFS Q1 Earnings
• Negative Sentiment: Multiple insider sales reported on the same filing period — EVP Aby Mathew sold 405 shares, CMO Todd Berard sold 344 shares, CFO Troy Wichterman sold 990 shares, plus additional smaller officer/insider sales (Sarah Aebersold, Karen Foster). All sales were executed around Jan 6 at ~ $25.59; while sizes are small relative to holdings, clustered executive selling can spook investors. Insider selling report

Wall Street Analyst Weigh In

BLFS has been the topic of several recent analyst reports. Northland Securities set a $34.00 target price on BioLife Solutions in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.